SG/CALL/ELI LILLY & CO/380/0.1/17.01.25 | Delayed Deutsche Boerse AG 13:25:48 24/06/2024 BST | ||
| 48.92 EUR | +1.47% |
|
| Current month | +16.39% | ||
| 1 month | +19.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 48.92 | +1.47% |
| 21/06/24 | 48.21 | +0.54% |
| 20/06/24 | 47.95 | -1.82% |
| 19/06/24 | 48.84 | +0.60% |
| 18/06/24 | 48.55 | +0.31% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 01:25 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ86XK |
| ISIN | DE000SQ86XK3 |
| Date issued | 16/02/2023 |
| Strike | 380 $ |
| Maturity | 17/01/2025 (207 Days) |
| Parity | 10 : 1 |
| Emission price | 5.38 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 49.45 € |
|---|---|
| Lowest since issue | 3.42 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
883.9
USD
Average target price
856.2
USD
Spread / Average Target
-3.13%
- Stock Market
- Warrants
- Warrant
